Ying Cheng

Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.

P. Jänne, D. Planchard, Y. Rukazenkov, 2023, The New England journal of medicine.

The efficacy and safety of immunotherapy as first−line treatment for extensive-stage small cell lung cancer: evaluating based on reconstructed individual patient data

Shuang Zhang, Ying Cheng, Shuang Li, 2024, Frontiers in Oncology.

Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (RATIONALE-312): a Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.

Dingzhi Huang, S. Leaw, Xingya Li, 2024, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CNS Efficacy of Osimertinib With or Without Chemotherapy in Epidermal Growth Factor Receptor–Mutated Advanced Non–Small-Cell Lung Cancer

P. Jänne, B. Chewaskulyong, D. Planchard, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2-targeting antibody drug conjugate FS-1502 in HER2-expressing metastatic breast cancer: a phase 1a/1b trial

Yongli Jin, Yunjiang Liu, Zhuli Wu, 2024, Nature communications.

A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma.

Xiaoting Wei, Jun Guo, R. Jiang, 2024, European journal of cancer.

Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial.

S. Fan, D. Ji, Yue Ma, 2024, European journal of cancer.

Vebreltinib for Advanced Non-Small Cell Lung Cancer Harboring c-Met Exon 14 Skipping Mutation: A Multicenter, Single-Arm, Phase II KUNPENG Study.

Dianqi Han, Yong Song, Yu Yao, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.